Australia's most trusted
source of pharma news
Posted 6 December 2023 AM
Anticipated blockbusters - Alnylam's RNAi therapeutic Amvuttra and BioMarin's gene therapy Roctavian - are among five innovative medicines recently accepted for review in Australia.
Amvuttra, previously known as vutrisiran, is a follow-up candidate to Alnylam's Onpattro and is intended for the treatment of hereditary transthyretin-mediated amyloidosis.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.